Assessing potential risks of treatment with long-term azithromycin in COPD patients: long-term oxygen users beware?
- PMID: 26502012
- DOI: 10.1007/s11845-015-1372-8
Assessing potential risks of treatment with long-term azithromycin in COPD patients: long-term oxygen users beware?
Abstract
Introduction: Long-term daily azithromycin therapy reduces the frequency of exacerbations in chronic obstructive pulmonary disease (COPD) in a randomized controlled clinical trial setting. Concerns exist regarding arrhythmic and auditory toxicities from chronic use in the real-world setting. We hypothesized that risk factors for adverse drug reactions to azithromycin would be more frequent than previously reported, that certain specific subgroups would have different frequencies of these risk factors and that the whispered voice test would be a useful test with which to test for hearing deficits.
Methods: Following ethical approval, 47 consecutive hospital-based patients with a mean age 69 years ± 8.2, and with physician-diagnosed COPD (mean FEV1 45.1 ± 18 % predicted), were screened for subjective hearing impairment (screening questions and whispered voice test) and by electrocardiogram for prolonged QTc. Other potential risk factors and contraindications to long-term daily azithromycin were sought.
Results: In total, 38 patients (80.9 %) had at least one risk factor or contraindication to azithromycin treatment. 19 patients (40.4 % of total) had subjective hearing impairment. 17 (36.1 %) had prolonged QTc intervals. 4 patients (8.51 %) had contraindicating co-morbidities. Those on long-term oxygen therapy were significantly more likely to have at least one risk factors or contraindications to azithromycin (p = 0.0025).
Conclusion: In a COPD population who would otherwise potentially be candidates for long-term daily azithromycin therapy, over 80 % had risk factors for complications from long-term daily azithromycin. Preventative treatment with long-term daily azithromycin may be appropriate for fewer COPD patients than previously thought, especially in those on long-term oxygen therapy.
Keywords: Azithromycin maintenance; Chronic obstructive pulmonary disease; Complications; Hearing loss; Screening.
Similar articles
-
Long-term azithromycin therapy to reduce acute exacerbations in patients with severe chronic obstructive pulmonary disease.Respir Med. 2018 May;138:129-136. doi: 10.1016/j.rmed.2018.03.035. Epub 2018 Apr 5. Respir Med. 2018. PMID: 29724384
-
Azithromycin for the Prevention of COPD Exacerbations: The Good, Bad, and Ugly.Am J Med. 2015 Dec;128(12):1362.e1-6. doi: 10.1016/j.amjmed.2015.07.032. Epub 2015 Aug 17. Am J Med. 2015. PMID: 26291905 Review.
-
Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial.Lancet Respir Med. 2014 May;2(5):361-8. doi: 10.1016/S2213-2600(14)70019-0. Epub 2014 Apr 15. Lancet Respir Med. 2014. PMID: 24746000 Clinical Trial.
-
Clinical and Safety Outcomes of Long-Term Azithromycin Therapy in Severe COPD Beyond the First Year of Treatment.Chest. 2018 May;153(5):1125-1133. doi: 10.1016/j.chest.2018.01.044. Epub 2018 Feb 7. Chest. 2018. PMID: 29427576
-
Preventing COPD exacerbations with macrolides: a review and budget impact analysis.Respir Med. 2013 May;107(5):637-48. doi: 10.1016/j.rmed.2012.12.019. Epub 2013 Jan 23. Respir Med. 2013. PMID: 23352223 Review.
Cited by
-
Effects of azithromycin on treating chronic obstructive pulmonary disease with acute exacerbation of chronic bronchitis in the stable phase.Am J Transl Res. 2021 Jun 15;13(6):7370-7375. eCollection 2021. Am J Transl Res. 2021. PMID: 34306507 Free PMC article.
-
Prophylactic macrolides for chronic obstructive pulmonary disease in the community: a decision for GPs.Br J Gen Pract. 2021 Dec 31;72(714):42-43. doi: 10.3399/bjgp22X718253. Print 2022 Jan. Br J Gen Pract. 2021. PMID: 34972807 Free PMC article. No abstract available.
-
Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD).Cochrane Database Syst Rev. 2018 Oct 30;10(10):CD009764. doi: 10.1002/14651858.CD009764.pub3. Cochrane Database Syst Rev. 2018. PMID: 30376188 Free PMC article.
-
Prophylactic antibiotics for adults with chronic obstructive pulmonary disease: a network meta-analysis.Cochrane Database Syst Rev. 2021 Jan 15;1(1):CD013198. doi: 10.1002/14651858.CD013198.pub2. Cochrane Database Syst Rev. 2021. PMID: 33448349 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical